Roche (RHHVF) Stock Price, News & Analysis

Company Overview

Roche Holding AG, traded on the OTCMKTS under the symbol RHHVF, is a leading global healthcare company with two core business divisions: Pharmaceuticals and Diagnostics. The company focuses on developing innovative medicines and diagnostic tests that address serious diseases, driving advances in personalized healthcare and precision medicine.

In its Pharmaceuticals division, Roche pioneers targeted therapies across oncology, immunology, ophthalmology and neuroscience. Flagship products include monoclonal antibodies and small-molecule treatments such as Herceptin, Avastin and Actemra, which have become standards of care for cancer and autoimmune conditions. Roche maintains a robust pipeline of investigational drugs supported by extensive research and development efforts.

The Diagnostics division offers a broad portfolio of in vitro tests, instruments and digital solutions used in hospitals, laboratories and point-of-care settings. Roche’s offerings span molecular diagnostics, immunodiagnostics and tissue-based testing, enabling early detection, monitoring and management of diseases ranging from infectious pathogens to chronic and rare disorders.

Founded in 1896 and headquartered in Basel, Switzerland, Roche serves patients and healthcare providers in more than 100 countries through a global network of affiliates and partnerships. Under the leadership of Chief Executive Officer Severin Schwan, the company continues to invest in cutting-edge research, strategic collaborations and digital health initiatives to advance personalized medicine and improve patient outcomes worldwide.

Key Stats

• Today's Range: $412.49 to $435.87
• 50-Day Range: $398.62 to $468.60
• 52-Week Range: $314.15 to $490.33
• Volume: 185 shs
• Average Volume: 12,916 shs
• Market Capitalization: N/A
• P/E Ratio: 39.85
• Dividend Yield: 1.81%
• Price Target: N/A
• Consensus Rating: N/A

Roche Stock Analysis - MarketRank™

Roche scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Roche.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Roche is 39.85, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.17.

Price to Earnings Ratio vs. Sector

The P/E ratio of Roche is 39.85, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.24.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Roche has a short interest ratio ("days to cover") of 169.39, which indicates bearish sentiment.

Change versus previous month

Short interest in Roche has recently increased by 12.92%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Roche pays a meaningful dividend of 3.21%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Roche does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Roche is 72.16%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.50

News Sentiment

Roche has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Roche this week, compared to 1 article on an average week.

MarketBeat Follows

2 people have added Roche to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Roche insiders have not sold or bought any company stock.

Percentage Held by Institutions

29.01% of the stock of Roche is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:RHHVF
• CIK: N/A
• Web: www.roche.com
• Phone: (161) 688-1111
• Fax: N/A
• Employees: 103,605
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 39.85
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A